Diagnostic utility and prognostic significance of the Ki‐67 labeling index in diffuse large B‐cell lymphoma transformed from follicular lymphoma: a study of 76 patients

2021 ◽  
Author(s):  
Akiko Miyagi Maeshima ◽  
Hirokazu Taniguchi ◽  
Yoshikazu Hori ◽  
Hanae Ida ◽  
Rika Hosoba ◽  
...  
2019 ◽  
Vol 6 (1) ◽  
pp. e07-e07
Author(s):  
Hossein Rahimi ◽  
Zahra Rezaei Borojerdi ◽  
Sajad Ataei Azimi ◽  
Elnaz Rashidian ◽  
Amirhossein Jafarian

Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common lymphatic neoplasm, accounting for about 30–40% of non-Hodgkin’s lymphoma cases. Objectives: DLBCL is a progressive disease with clinical, genetic and molecular heterogeneity. The prognostic value of B-cell lymphoma 2 (BCL2) and Ki-67 in DLBCL patients has been controversial. Patients and Methods: In this study, we investigated the correlation of BCL2 and Ki-67 expression with clinical features such as age, gender, B symptoms and lactate dehydrogenase (LDH) levels, subtypes of DLBCL, its staging and prognosis in 36 cases of DLBCL. The expression of BCL2 and Ki-67 was measured by immunohistochemistry. Results: There was no significant correlation between BCL2 expression and staging (P=0.082), however Ki-67 expression had a significant correlation with staging (P=0.002). There was no statistically significant correlation between BCL2 and Ki-67 with prognosis of the disease. We found a significant correlation between the germinal center B-cell (GCB) and non- GCB subtypes with BCL2 expression (P=0.024), since patients with non- GCB subtype had a higher BCL2 expression. Our study also demonstrated a significant relationship between BCL2 and Ki-67 expression, therefore, with the increase of the expression of a marker, another increases (P=0.045). Conclusion: BCL2 and Ki-67 expressions were not associated with prognosis. Overexpression of Ki-67 was associated with higher clinical stages. BCL2 expression is higher in non-GCB subtype of DLBCL. Therefore, our study shows that the subsequent studies of BCL2 and other biomarkers in the DLBCL should be based on the DLBCL subtypes.


2016 ◽  
Vol 2016 ◽  
pp. 1-3
Author(s):  
Elham Vali Betts ◽  
Hooman H. Rashidi

Diffuse large B-cell lymphoma (DLBCL) is a neoplasm of large B-lymphocytes with a diffuse growth pattern. The neoplastic cells express B-cell markers such as CD20 and PAX-5 and there may be coexpression of BCL-2, BCL-6, CD10, and MUM-1. With the exception of CD5, other T-cell markers are not commonly expressed in this neoplasm. Here, we describe the first reported case of a DLBCL with abnormal expression CD7 arising in a background of follicular lymphoma in an 81-year-old male who presented with a nontender left axillary mass. Additionally, no other T-cell antigens were expressed in this B-cell lymphoma. Expression of CD7 in DLBCL is exceptionally rare and its prognostic significance is unknown. Here, we describe this rare case with review of literature of known DLBCLs with expression of T-cell antigens.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 4631-4631
Author(s):  
Sun-Jin Sym ◽  
Sung Sook Lee ◽  
Min Kyoung Kim ◽  
Shin Kim ◽  
Cheolwon Suh

Abstract The cell proliferation rate of tumors from patients with non-Hodgkin’s lymphomas has been shown to correlate with survival in previous studies. The aim of this study was to evaluate the independent prognostic value of Ki-67 expression level and the significance of cell proliferation rate as an outcome predictor. To this end, we reviewed the hospital case records and histopathological materials of 92 patients diagnosed with diffuse large B-cell lymphoma in a single center. The cell proliferative rate was expressed as percentage of Ki-67 positive cells (Ki-67 labeling index). All patients were available Ki-67 expression level. High Ki-67 labeling index was defined as nuclear Ki-67 expression in ≥ 70% of malignant cells. A cutoff point of 70% was used because this divided the group of cases into two subgroups of similar size (Ki-67 labeling index < 70, n = 46, Ki-67 labeling index ≥ 70, n = 46). The median age was 57 years (range, 15 to 83 years). The median follow-up time was 14 months. Sixty-nine (75%) patients were treated R-CHOP regimen initially and 13 (14%) patients were CHOP regimen. In a univariate analysis, age (p =.003), performance (p =.001), serum LDH (p =.020) were significant prognostic factors for overall survival. But Ki-67 had no statistical significance (p =.554). Multivariate analysis used Cox’s multivariate regression model revealed that serum LDH (relative risk estimate 6.7; 95% confidence interval, 1.5, 30.5), age (relative risk estimate 7.0; 95% confidence interval, 1.9, 26.4) were independent prognostic factors for overall survival. Taking all the results into consideration, it seems that Ki-67 expression level has no significance as outcome predictor in Korean diffuse large B-cell lymphoma.


2001 ◽  
Vol 18 (1) ◽  
pp. 15-22 ◽  
Author(s):  
Marta Llanos ◽  
Hugo Alvarez-Argüelles ◽  
Remedios Alemán ◽  
Juana Oramas ◽  
Lucio Díaz-Flores ◽  
...  

Author(s):  
Carla Isabelly Rodrigues‐Fernandes ◽  
Lucas Guimarães Abreu ◽  
Raghu Radhakrishnan ◽  
Danyel Elias da Cruz Perez ◽  
Gleyson Kleber Amaral‐Silva ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document